CHMA Chiasma Inc.

5.09
+0.04  (+1%)
Previous Close 5.05
Open 5.02
Price To Book 4.17
Market Cap 212,696,985
Shares 41,787,227
Volume 197,162
Short Ratio
Av. Daily Volume 373,035
Stock charts supplied by TradingView

NewsSee all news

  1. Chiasma to Present at the Cantor 2019 Global Healthcare Conference

    WALTHAM, Mass., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today

  2. Chiasma Hosting Key Opinion Leader Meeting on Maintenance Therapy of Adult Patients with Acromegaly

    WALTHAM, Mass., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, will host a

  3. Chiasma to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    WALTHAM, Mass., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today

  4. Aleta Biotherapeutics Announces Appointments to Board of Directors

    Mark Leuchtenberger joins Board as Executive Chairman Eva-Lotta Allan appointed as Non-Executive Director Aleta Biotherapeutics, a privately held immuno-oncology company focused on transforming cellular

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

NDA filing due 4Q 2019.
Mycapssa - OPTIMAL
Acromegaly
CRL April 15 2016
Mycapssa
Acromegaly
Phase 3 data due 2H 2020.
Mycapssa - MPOWERED
Maintenance treatment of adult acromegaly

Latest News

  1. Chiasma to Present at the Cantor 2019 Global Healthcare Conference

    WALTHAM, Mass., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today

  2. Chiasma Hosting Key Opinion Leader Meeting on Maintenance Therapy of Adult Patients with Acromegaly

    WALTHAM, Mass., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, will host a

  3. Chiasma to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    WALTHAM, Mass., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today

  4. Aleta Biotherapeutics Announces Appointments to Board of Directors

    Mark Leuchtenberger joins Board as Executive Chairman Eva-Lotta Allan appointed as Non-Executive Director Aleta Biotherapeutics, a privately held immuno-oncology company focused on transforming cellular